Study guide

8.2 Lower GI Disorders: Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD) & Diverticular Disease

ANCC Adult-Gerontology Primary Care Nurse Practitioner AGPCNP-BC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The AGPCNP-BC Examination: Blueprint, Format & Scoring

1.1 The AGPCNP-BC Blueprint, Exam Format, Scoring, Eligibility & Renewal

2 Chapter 2: Assessment Foundations & Lifespan Considerations

2.1 Comprehensive Health History, Symptom Analysis & Lifespan Variations 2.2 Physical Examination Techniques & Age-Related Physiological Changes 2.3 Functional Assessment (Katz ADL / Lawton IADL) & Frailty Syndromes 2.4 Psychosocial, Nutritional, Cognitive & Mental Health Screening Instruments 2.5 Health Screening Guidelines (USPSTF) & Adult Immunization Schedules (CDC/ACIP)

3 Chapter 3: Diagnostic Reasoning & Clinical Interpretation

3.1 Diagnostic Reasoning, Clinical Decision-Making & Differential Diagnosis Formulation 3.2 Routine & Specialized Laboratory Interpretation 3.3 Diagnostic Imaging, ECG Interpretation & Pulmonary Function Testing 3.4 Evidence-Based Testing, Pre-Test Probability & Choosing Wisely Principles

4 Chapter 4: Cardiovascular Disorders

4.1 Hypertension: 2025 AHA/ACC Guideline, Resistant HTN & Secondary HTN 4.2 Dyslipidemia & ASCVD Risk Calculation, Statin Therapy & Non-Statin Agents 4.3 Coronary Artery Disease, Stable Angina & Post-ACS Outpatient Management 4.4 Heart Failure (HFrEF/HFpEF), Atrial Fibrillation & Peripheral Vascular Disease

5 Chapter 5: Respiratory Disorders

5.1 Asthma: GINA 2026 Guidelines, Phenotypes, Stepwise Pharmacotherapy & Action Plans 5.2 COPD: GOLD 2026 Report, ABE Staging, Triple Inhalers & Exacerbations 5.3 Lower Respiratory Infections (CAP, Bronchitis), Pleural Disease & Solitary Pulmonary Nodules

6 Chapter 6: HEENT & Allergic/Immunologic Disorders

6.1 Eye & Vision Disorders in Adult-Gerontology Primary Care 6.2 Ear, Hearing & Vestibular Disorders 6.3 Nose, Sinus, Oropharyngeal & Oral Cavity Disorders 6.4 Allergic & Immunologic Disorders: Anaphylaxis, Urticaria, Angioedema & Immunodeficiency

7 Chapter 7: Endocrine & Metabolic Disorders

7.1 Type 2 Diabetes Mellitus: ADA Standards of Care, Pharmacotherapy & Microvascular Complications 7.2 Thyroid Disorders: Hypothyroidism, Hyperthyroidism, Thyroiditis & Nodules 7.3 Adrenal & Pituitary Disorders: Adrenal Insufficiency, Cushing's, Hyperaldosteronism & Hypopituitarism 7.4 Metabolic Bone Disease: Osteopenia, Osteoporosis (FRAX, DEXA) & Hyperparathyroidism

8 Chapter 8: Gastrointestinal & Hepatic Disorders

8.1 Upper GI Disorders: GERD, Barrett's Esophagus, PUD, H. pylori & Gastritis 8.2 Lower GI Disorders: Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD) & Diverticular Disease 8.3 Hepatobiliary Disorders: MASLD/MASH, Viral & Alcoholic Hepatitis, Cirrhosis & Cholelithiasis 8.4 Acute & Chronic Abdominal Pain Syndromes, GI Bleeding & Colorectal Cancer Screening

9 Chapter 9: Renal, Urological & Men's Health

9.1 Chronic Kidney Disease: KDIGO Staging, Albuminuria Management & Renoprotective Strategies 9.2 Urinary Tract Infections (Uncomplicated, Complicated, Recurrent), Pyelonephritis & Microscopic Hematuria 9.3 Men's Health: Benign Prostatic Hyperplasia, Prostatitis, Epididymitis & Erectile Dysfunction

10 Chapter 10: Musculoskeletal & Rheumatologic Disorders

10.1 Degenerative & Overuse Musculoskeletal Disorders: Osteoarthritis, Tendinopathies & Spine Disorders 10.2 Autoimmune Rheumatologic Disorders: Rheumatoid Arthritis, SLE, Polymyalgia Rheumatica & Giant Cell Arteritis 10.3 Crystal Arthropathies & Fibromyalgia: Gout, Pseudogout & Centralized Pain Syndromes

11 Chapter 11: Neurological & Psychiatric Disorders

11.1 Headaches (Migraine, Tension, Cluster) & Cranial Neuralgias 11.2 Cerebrovascular Disease, TIA, Peripheral Neuropathies & Movement Disorders (Parkinson's) 11.3 Mood & Anxiety Disorders: Major Depressive Disorder, Generalized Anxiety Disorder & PTSD 11.4 Substance Use Disorders: Alcohol, Tobacco, Opioids & Cannabis in Primary Care

12 Chapter 12: Dermatologic, Hematologic & Infectious Disease

12.1 Primary Dermatologic Lesions, Inflammatory Dermatoses & Cutaneous Malignancies 12.2 Common Infectious Diseases: Skin/Soft Tissue Infections, Tick-Borne Illnesses & Viral Syndromes 12.3 Sexually Transmitted Infections (STIs): CDC Guidelines, Screening & Partner Management 12.4 Hematologic Disorders: Anemias (Microcytic, Normocytic, Macrocytic), Leukopenia & Coagulopathies

13 Chapter 13: Geriatric Syndromes, Pharmacology & Palliative Care

13.1 The Geriatric 5Ms Framework, Multimorbidity & Polypharmacy Deprescribing 13.2 Beers Criteria 2023 Update & STOPP/START Prescribing Rules 13.3 Pharmacokinetics, Pharmacodynamics & Pharmacogenomics Across the Adult Lifespan 13.4 Dementia vs. Delirium vs. Depression: Differential Diagnostics & Management 13.5 Falls, Mobility Impairment, Pressure Injury Prevention & Palliative Care Transitions

14 Chapter 14: Gynecologic & Women's Health

14.1 Contraceptive Management, Emergency Contraception & Preconception Counseling 14.2 Perimenopause, Menopause & Hormone Replacement Therapy (HRT) 14.3 Gynecologic Infections (Vaginitis, PID), Abnormal Uterine Bleeding & Cervical Cancer Screening (USPSTF/ASCCP)

15 Chapter 15: Plan-of-Care Process: Behavior Change, Education & Care Coordination

15.1 Behavioral Change: Motivational Interviewing, Models & Theories 15.2 Patient Education, Shared Decision-Making, Referrals, Care Coordination & Plan Reassessment

16 Chapter 16: APRN Professional Practice, Ethics, Policy & Quality Improvement

16.1 APRN Scope of Practice, Consensus Model, Collaborative Practice & Credentialing 16.2 Bioethics, Informed Consent, Advance Directives & Surrogate Decision-Making 16.3 Environmental & Social Determinants of Health, Health Equity & Culturally Responsive Care 16.4 Evidence-Based Practice (EBP), Quality Improvement (QI) Methodologies & Healthcare Economics

8.2 Lower GI Disorders: Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD) & Diverticular Disease

Key Takeaways Explain This Topic AI

Irritable Bowel Syndrome (IBS) is diagnosed via the Rome IV criteria (recurrent abdominal pain ≥1 day/week over the past 3 months associated with defecation, stool frequency changes, or stool form changes) in the absence of alarm features (age ≥50, nocturnal diarrhea, rectal bleeding, unexplained weight loss, or anemia).

Ulcerative Colitis (UC) is characterized by continuous, mucosal-only inflammation starting at the rectum and extending proximally into the colon, presenting with bloody diarrhea and tenesmus, whereas Crohn's Disease (CD) features transmural, skip-lesion inflammation anywhere from mouth to anus, presenting with non-bloody or bloody diarrhea, crampy RLQ pain, strictures, and perianal fistulas.

Fecal Calprotectin is a highly sensitive non-invasive biomarker of intestinal mucosal inflammation used to distinguish active IBD from functional disorders like IBS and monitor therapeutic mucosal healing.

Patients with extensive IBD colitis require screening colonoscopy with chromoendoscopy starting 8 years after symptom onset, repeated every 1 to 3 years, due to markedly elevated colorectal cancer risk; patients with concurrent Primary Sclerosing Cholangitis (PSC) require annual colonoscopy starting immediately upon diagnosis.

Acute Diverticulitis presents with constant LLQ pain, fever, and leukocytosis; Abdominal CT with IV contrast is the gold-standard diagnostic imaging modality, whereas colonoscopy and barium enema are strictly contraindicated during an acute flare due to the risk of mechanical perforation and peritonitis.

Last updated: August 2026

Lower GI Disorders: Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD) & Diverticular Disease

Lower gastrointestinal disorders span a continuum from benign functional gastrointestinal disorders (FGIDs) to life-threatening chronic inflammatory bowel diseases and acute surgical emergencies. The Adult-Gerontology Primary Care Nurse Practitioner must demonstrate expert competency in applying standardized diagnostic criteria, recognizing clinical red flags, interpreting non-invasive inflammatory biomarkers, managing advanced immunosuppressive and biologic therapies, and preventing severe complications.

  • 1. Irritable Bowel Syndrome (IBS)
  • Pathophysiology & Brain-Gut Axis Dysregulation

IBS is a disorder of gut-brain interaction characterized by altered gastrointestinal motility, visceral hypersensitivity , impaired intestinal mucosal permeability, low-grade immune activation, and altered gut microbiome composition. Bidirectional signaling between the central nervous system and the enteric nervous system (the brain-gut axis) amplifies visceral pain perception in response to physiological intraluminal distension. +-----------------------------------------------------------------------------+

  • | ROME IV CRITERIA FOR IBS |
  • | |
  • | Recurrent abdominal pain on average at least 1 DAY PER WEEK in the last |
  • | 3 MONTHS, with symptom onset at least 6 MONTHS prior to diagnosis, |
  • | associated with TWO OR MORE of the following criteria: |
  • | |
  • | 1. Related to DEFECATION (either improvement or worsening of pain). |
  • | 2. Associated with a change in the FREQUENCY of stool. |
  • | 3. Associated with a change in the FORM (appearance) of stool |
  • | (evaluated via the Bristol Stool Form Scale). |
  • +-----------------------------------------------------------------------------+

Bristol Stool Form Scale & IBS Subtyping +-----------------------------------------------------------------------------+

  • | BRISTOL STOOL FORM SCALE (BSFS) |
  • | |
  • | [Type 1] - Separate hard lumps, like nuts (hard to pass) --> CONSTIPATION|
  • | [Type 2] - Sausage-shaped but lumpy --> CONSTIPATION|
  • | [Type 3] - Like a sausage with cracks on the surface --> NORMAL |
  • | [Type 4] - Like a sausage or snake, smooth and soft --> NORMAL |
  • | [Type 5] - Soft blobs with clear-cut edges --> DIARRHEA |
  • | [Type 6] - Fluffy pieces with ragged edges, mushy --> DIARRHEA |
  • | [Type 7] - Watery, no solid pieces; entirely liquid --> DIARRHEA |
  • +-----------------------------------------------------------------------------+

IBS-C (Constipation Predominant): > 25% of bowel movements are BSFS Type 1 or 2, and < 25% are BSFS Type 6 or 7.

IBS-D (Diarrhea Predominant): > 25% of bowel movements are BSFS Type 6 or 7, and < 25% are BSFS Type 1 or 2.

IBS-M (Mixed Bowel Habits): > 25% of bowel movements are Type 1 or 2, AND > 25% are Type 6 or 7.

IBS-U (Unclassified): Insufficient abnormality of stool consistency to meet criteria for IBS-C, D, or M.

Alarm Features Excluding Simple IBS (Mandating Diagnostic Workup / Colonoscopy) +-----------------------------------------------------------------------------+

  • | IBS "ALARM FEATURES" (RED FLAGS) |
  • | |
  • | * Symptom onset at age >= 50 years |
  • | * Nocturnal diarrhea awakening patient from sound sleep |
  • | * Overt rectal bleeding or hematochezia (not attributable to hemorrhoids) |
  • | * Unexplained, progressive, unintentional weight loss |
  • | * Unexplained Iron Deficiency Anemia (IDA) or elevated inflammatory labs |
  • | * Palpable abdominal mass or localized lymphadenopathy |
  • | * Family history of Colorectal Cancer, IBD, or Celiac Disease in a |
  • | 1st-degree relative |
  • | * Progressive, daily, unremitting pain |
  • +-----------------------------------------------------------------------------+
  • Diagnostic Strategy & Rational Workup

In a young or middle-aged patient presenting with classic Rome IV criteria and no alarm features , extensive routine testing is unnecessary and discouraged:

Routine Labs: Complete Blood Count (CBC) to screen for anemia; C-Reactive Protein (CRP) or Fecal Calprotectin to exclude active mucosal inflammation.

Celiac Serology: Tissue Transglutaminase IgA (tTG-IgA) PLUS total serum IgA (to rule out celiac sprue, especially in IBS-D and IBS-M).

Stool Studies (in IBS-D): Giardia antigen, routine stool enteric bacterial cultures, and C. difficile PCR if recent antibiotics.

Evidence-Based Treatment Algorithm for IBS

IBS Subtype First-Line Lifestyle & Dietary Second-Line / Targeted Pharmacotherapy Mechanisms & Clinical Pearls

All Subtypes - Low-FODMAP Diet (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols) trial x 4–6 weeks under dietitian guidance.; - Soluble Fiber: Psyllium (Ispaghula husk) 20–30 g/day (avoid insoluble wheat bran; worsens gas/bloating!).; - Structured exercise, gut-directed CBT. - Antispasmodics (as needed): Dicyclomine (10–20 mg QID), Hyoscyamine (0.125–0.25 mg sublingual/oral Q4H PRN).; - Neuromodulators (for chronic pain): Tricyclic Antidepressants (TCAs: Amitriptyline 10–25 mg QHS) or SSRIs. Antispasmodics block muscarinic receptors on gut smooth muscle. TCAs slow transit via anticholinergic effects and downregulate visceral central pain pathways.

IBS-C Increase fluid intake, dietary soluble fiber. - Osmotic Laxatives: Polyethylene glycol (PEG 3350) 17 g daily.; - Intestinal Secretagogues: ; * Lubiprostone: 8 mcg BID (Chloride channel-2 activator).; * Linaclotide: 72–290 mcg daily (Guanylate cyclase-C agonist; increases cGMP, chloride/bicarbonate secretion).; * Plecanatide: 3 mg daily (GC-C agonist).; - 5-HT4 Agonist: Tegaserod (females <65 without CV risk). GC-C agonists and Lubiprostone accelerate intestinal transit and reduce visceral nociceptive nerve firing. Common side effect: diarrhea.

IBS-D Low-FODMAP diet; eliminate lactose, caffeine, artificial sweeteners (sorbitol). - Opioid Agonists: Loperamide (2–4 mg PRN before meals).; - Eluxadoline: 75–100 mg BID (Mixed mu-/kappa-opioid agonist, delta-antagonist).; - Rifaximin: 550 mg TID for 14 days (Non-absorbable antibiotic; modulates microbiome).; - 5-HT3 Antagonist: Alosetron (0.5–1 mg BID; restricted to women with severe refractory IBS-D; REMS program for ischemic colitis). Eluxadoline Contraindications: Prior cholecystectomy, history of pancreatitis, alcohol abuse, or biliary obstruction (causes severe Sphincter of Oddi spasm and acute pancreatitis!).

2. Inflammatory Bowel Disease (IBD): Crohn's Disease vs. Ulcerative Colitis

Inflammatory Bowel Disease comprises two major chronic, idiopathic, immune-mediated relapsing inflammatory disorders of the gastrointestinal tract: Crohn's Disease (CD) and Ulcerative Colitis (UC) . +-----------------------------------------------------------------------------+

  • | CROHN'S DISEASE vs. ULCERATIVE COLITIS |
  • | |
  • | FEATURE CROHN'S DISEASE (CD) ULCERATIVE COLITIS (UC)|
  • | ----------------------------------------------------------------------- |
  • | Anatomical Location ANY segment from MOUTH COLON ONLY |
  • | to ANUS ("Gum to Bum"). Starts at RECTUM and |
  • | Terminal ileum + cecum extends proximally in |
  • | most common (50%). CONTINUOUS fashion. |
  • | |
  • | Pattern of Lesions "SKIP LESIONS" CONTINUOUS, UNBROKEN |
  • | (patches of normal bowel mucosal inflammation; |
  • | between diseased segments). NO skip areas. |
  • | |
  • | Depth of Inflammation TRANSMURAL (entire wall MUCOSA and SUBMUCOSA |
  • | thickness: mucosa to ONLY (superficial |
  • | serosa). layers). |
  • | |
  • | Endoscopic Appearance "Cobblestone" appearance, Continuous erythema, |
  • | deep linear/serpiginous loss of vascularity, |
  • | ulcers, aphthoid ulcers. friability, pseudo- |
  • | polyps, shallow ulcers.|
  • | |
  • | Histopathology NON-CASEATING GRANULOMAS CRYPT ABSCESSES, crypt |
  • | (pathognomonic in ~30%), distortion, absence |
  • | transmural lymphoid aggregates. of true granulomas.|
  • | |
  • | Dominant Clinical Signs Crampy RLQ pain, chronic BLOODY DIARRHEA with |
  • | diarrhea (often non-bloody) mucus, severe TENESMUS|
  • | weight loss, low-grade fever fecal urgency, LLQ |
  • | aphthous oral ulcers. crampy pain. |
  • | |
  • | Structural Complications STRICTURES (obstruction), TOXIC MEGACOLON |
  • | FISTULAS (perianal, (colonic diameter >6cm)|
  • | enterocutaneous, entero- Massive hemorrhage, |
  • | vesical), PERIANAL ABSCESS Colorectal Cancer. |
  • | |
  • | Malabsorption / Deficits Vitamin B12 deficiency Iron deficiency anemia |
  • | (terminal ileal disease), due to chronic rectal |
  • | bile acid diarrhea, blood loss. |
  • | gallstones, oxalate stones. |
  • | |
  • | Serologic Biomarkers ASCA Positive p-ANCA Positive |
  • | (Anti-Saccharomyces) (Perinuclear ANCA) |
  • | p-ANCA Negative (usually) ASCA Negative (usually)|
  • | |
  • | Cigarette Smoking Role SMOKING WORSENS DISEASE SMOKING IS PROTECTIVE |
  • | (higher recurrence/surgery)(cessation may flare!) |
  • | |
  • | Surgical Role Non-curative (disease CURATIVE (Total |
  • | recurs at anastomoses); proctocolectomy with |
  • | reserved for strictures. ileal pouch-anal IPAA).|
  • +-----------------------------------------------------------------------------+
  • Extraintestinal Manifestations (EIMs) of IBD

Extraintestinal manifestations occur in up to 40% of IBD patients and are classified based on whether their clinical activity parallels active bowel inflammation: +-----------------------------------------------------------------------------+

  • | EXTRAINTESTINAL MANIFESTATIONS (EIMs) |
  • | |
  • | A. PARALLEL TO BOWEL INFLAMMATION (Improve with GI disease remission): |
  • | 1. Peripheral Arthropathy: Non-deforming, asymmetric, large joint |
  • | pauciarticular arthritis (knees, ankles, wrists). |
  • | 2. Erythema Nodosum: Tender, painful, erythematous subcutaneous nodules|
  • | typically over the anterior pretibial surfaces. |
  • | 3. Episcleritis: Benign inflammatory injection of episclera; ocular |
  • | redness and irritation without visual loss. |
  • | 4. Aphthous Stomatitis: Recurrent, painful shallow oral ulcers. |
  • | |
  • | B. INDEPENDENT OF BOWEL INFLAMMATION (Run a separate clinical course): |
  • | 1. Axial Spondylitis / Sacroiliitis: Ankylosing spondylitis strongly |
  • | associated with HLA-B27; causes progressive spinal stiffening. |
  • | 2. Pyoderma Gangrenosum: Severe, rapidly progressive, painful necrotic |
  • | ulcerations with purplish/violaceous undermined borders; exhibits |
  • | PATHERGY (worsened by surgical debridement!). |
  • | 3. Anterior Uveitis / Iritis: Deep ocular pain, photophobia, blurred |
  • | vision; represents an ophthalmologic emergency. |
  • | 4. Primary Sclerosing Cholangitis (PSC): Progressive cholestatic |
  • | fibrosing inflammation of bile ducts ("onion-skin" strictures); |
  • | strongly linked to Ulcerative Colitis (70-80%); markedly increases |
  • | risk of Cholangiocarcinoma and Colorectal Cancer! |
  • +-----------------------------------------------------------------------------+

Pharmacotherapy and Biologic Management in IBD +-----------------------------------------------------------------------------+

  • | IBD THERAPEUTIC PYRAMID |
  • | |
  • | [LEVEL 1: 5-AMINOSALICYLATES (5-ASAs)] |
  • | - Mesalamine (oral and topical suppository/enema), Sulfasalazine. |
  • | - First-line for induction and maintenance of MILD-TO-MODERATE UC. |
  • | - Sulfasalazine requires mandatory FOLIC ACID co-supplementation (1 mg/d).|
  • | |
  • | [LEVEL 2: CORTICOSTEROIDS (INDUCTION ONLY)] |
  • | - Oral Prednisone, IV Methylprednisolone, Oral Budesonide (controlled- |
  • | ileal release formulation with high first-pass hepatic metabolism; |
  • | ideal for mild-to-moderate ileocecal Crohn's disease). |
  • | - STRICT RULE: Used solely for ACUTE INDUCTION. NEVER for maintenance! |
  • | |
  • | [LEVEL 3: IMMUNOMODULATORS] |
  • | - Azathioprine (AZA), 6-Mercaptopurine (6-MP), Methotrexate (for CD). |
  • | - MANDATORY PRE-TREATMENT TESTING: TPMT (Thiopurine Methyltransferase) |
  • | and NUDT15 genotype/phenotype to prevent life-threatening bone marrow |
  • | toxicity and severe leukopenia. |
  • | |
  • | [LEVEL 4: BIOLOGICS & TARGETED SMALL MOLECULES] |
  • | - Anti-TNF Agents: Infliximab (IV), Adalimumab (SC), Certolizumab (SC), |
  • | Golimumab (SC). MANDATORY PRE-SCREENING FOR LATENT TB (QuantiFERON-TB) |
  • | AND HEPATITIS B (HBsAg, Anti-HBc) to avoid fatal reactivation! |
  • | - Anti-Integrin: Vedolizumab (gut-selective alpha4-beta7 blocker). |
  • | - Anti-IL-12/23: Ustekinumab, Risankizumab, Mirikizumab. |
  • | - JAK Inhibitors: Tofacitinib, Upadacitinib (boxed warning: thrombosis). |
  • | - S1P Modulators: Ozanimod (requires baseline ECG, eye exam for macular |
  • | edema, VZV immunity check). |
  • +-----------------------------------------------------------------------------+
  • Colorectal Cancer Surveillance Protocols in IBD

Patients with extensive ulcerative colitis (pancolitis or left-sided colitis) and Crohn's colitis involving >1/3 of the colon have a significantly elevated risk of colorectal cancer due to chronic mucosal inflammation.

Initial Screening Colonoscopy: Recommended 8 years after symptom onset for all patients with extensive colitis.

Surveillance Frequency: Every 1 to 3 years using high-definition chromoendoscopy with targeted biopsies.

Special High-Risk Category: Patients with concurrent Primary Sclerosing Cholangitis (PSC) must begin annual colonoscopic surveillance immediately upon PSC diagnosis , regardless of disease duration.

  • 3. Diverticular Disease: Diverticulosis vs. Acute Diverticulitis
  • Definitions & Pathophysiology

Diverticulosis: The presence of uninflamed "pseudodiverticula" (false diverticula consisting of mucosal and submucosal herniations through the muscularis propria at weak points where nutrient arteries [vasa recta] penetrate the circular muscle layer). Most commonly located in the sigmoid and descending colon (95% in Western populations) due to high intraluminal pressure and low-fiber dietary patterns.

Diverticular Hemorrhage: Painless, massive, acute lower gastrointestinal bleeding (hematochezia) caused by mechanical shear stress and rupture of the exposed vasa recta at the neck or dome of a diverticulum. Responsible for 30% to 40% of all major lower GI bleeds. Spontaneously resolves in ~80% of cases.

Acute Diverticulitis: Acute inflammation and infection of a diverticular sac caused by micro- or macro-perforation of the diverticular wall, resulting in localized pericolic inflammation, phlegmon, abscess, or free peritonitis. +-----------------------------------------------------------------------------+

  • | DIVERTICULOSIS vs. ACUTE DIVERTICULITIS |
  • | |
  • | FEATURE DIVERTICULOSIS ACUTE DIVERTICULITIS |
  • | ----------------------------------------------------------------------- |
  • | Symptom Profile Asymptomatic in 85%; CONSTANT, SEVERE LLQ |
  • | occasional mild cramping pain, fever, chills, |
  • | or painless brisk bleeding nausea, bowel changes |
  • | Physical Exam Completely normal LLQ tenderness, mass, |
  • | localized guarding |
  • | Inflammatory Markers Normal CBC and CRP Leukocytosis with |
  • | left shift, high CRP |
  • | Diagnostic Test Incidental on colonoscopy ABDOMINAL CT WITH |
  • | or CT imaging INTRAVENOUS CONTRAST |
  • | Colonoscopy Status Safe and routine STRICTLY CONTRAINDICATED|
  • | during acute phase! |
  • | Dietary Strategy HIGH-FIBER (25-35 g/day); ACUTE: Clear liquids |
  • | Hydration (No need to RECOVERY: Advance diet |
  • | avoid seeds/nuts/corn!) LONG-TERM: High-fiber |
  • +-----------------------------------------------------------------------------+
  • Clinical Presentation of Acute Diverticulitis

Hallmark Symptoms: Steady, severe, aching pain localized to the Left Lower Quadrant (LLQ) (can present as Right Lower Quadrant pain in Asian populations with cecal/right-sided diverticulosis), low-grade fever (38.0–38.5°C), anorexia, nausea, constipation (50%) or diarrhea (30%), and dysuria/frequency if the inflamed sigmoid abuts the urinary bladder (sympathetic bladder irritability).

Physical Examination: Tenderness to palpation in the LLQ, possible tender palpable inflammatory mass, voluntary guarding; involuntary rigidity and diffuse rebound tenderness indicate free perforation and generalized peritonitis.

Diagnostic Evaluation & Modified Hinchey Classification

Diagnostic Modality of Choice: Contrast-Enhanced CT of the Abdomen and Pelvis (Sensitivity > 95%, Specificity > 95%).

Characteristic CT Findings: Colonic wall thickening (> 4 mm), pericolic fat stranding, presence of diverticula, intramural or pelvic abscess, extraluminal air, or contrast extravasation.

Absolute Contraindication: Colonoscopy, flexible sigmoidoscopy, and barium enemas are STRICTLY CONTRAINDICATED during the acute episode due to the high risk of converting a contained microperforation into a catastrophic free peritoneal perforation from intraluminal air insufflation!

Post-Recovery Colonoscopy Mandate: Schedule a complete diagnostic colonoscopy 6 to 8 weeks after complete resolution of the acute flare to definitively exclude underlying colonic adenocarcinoma (which can mimic diverticulitis on CT in up to 1% to 2% of cases). +-----------------------------------------------------------------------------+

  • | MODIFIED HINCHEY STAGING & MANAGEMENT |
  • | |
  • | HINCHEY STAGE DESCRIPTION CLINICAL MANAGEMENT |
  • | ----------------------------------------------------------------------- |
  • | Stage Ia Confined pericolic Outpatient oral abx / |
  • | phlegmon / inflammation selective observation |
  • | |
  • | Stage Ib Confined pericolic Abscess < 3-4 cm: IV abx |
  • | or mesocolic ABSCESS Abscess >= 4 cm: CT-guided|
  • | percutaneous drainage |
  • | |
  • | Stage II Pelvic, distant CT-guided percutaneous |
  • | intra-abdominal abscess drainage + IV abx |
  • | |
  • | Stage III Generalized PURULENT Emergency surgical |
  • | peritonitis (ruptured) laparotomy / Hartmann's |
  • | |
  • | Stage IV Generalized FECULENT Emergency surgical |
  • | peritonitis (feces) laparotomy + colostomy |
  • +-----------------------------------------------------------------------------+
  • Guideline-Directed Management of Acute Diverticulitis (AGA / ASCRS Guidelines)

Uncomplicated Diverticulitis in Immunocompetent Outpatients:

Selective Antibiotic Use (AGA Update): In healthy, immunocompetent patients with mild, uncomplicated diverticulitis, robust social support, and no systemic toxic features, a non-antibiotic strategy consisting of a clear liquid diet for 48–72 hours with close 48-hour follow-up is safe and effective.

Outpatient Antibiotic Indications: Mandatory for high-risk patients: older adults, immunocompromised status, significant comorbid disease (DM, CKD, cirrhosis), high fever (> 38.5°C), severe leukocytosis, inability to tolerate oral fluids, or failure of conservative management.

First-Line Outpatient Oral Antibiotic Regimens (Duration: 7 to 10 days):

Monotherapy: Amoxicillin-Clavulanate (Augmentin) 875/125 mg orally twice daily (BID).

Combination Therapy: Ciprofloxacin 500 mg orally BID (or Levofloxacin 500 mg daily) PLUS Metronidazole 500 mg orally TID.

Alternative for Fluoroquinolone Intolerance: Cefdinir 300 mg BID (or Cefuroxime 500 mg BID) PLUS Metronidazole 500 mg TID; OR Trimethoprim-Sulfamethoxazole (TMP-SMX DS) 1 tab BID PLUS Metronidazole 500 mg TID.

Inpatient Hospitalization Indications:

Complicated diverticulitis (Hinchey Ib–IV: abscess, perforation, fistula, obstruction).

High fever, severe sepsis, hemodynamic instability, diffuse peritonitis.

Inability to tolerate oral hydration or medications (intractable nausea/vomiting).

Frail geriatric patients, severe immunosuppression (transplant, chemotherapy, high-dose steroids), failed outpatient therapy after 48–72 hours.

Inpatient IV Regimens: Piperacillin-Tazobactam (Zosyn) 3.375g IV Q6H; OR Ceftriaxone 2g IV daily + Metronidazole 500mg IV Q8H.